A Phase 2 Study of Lower-Dose Cyclophosphamide to Prevent GVHD in Adults Receiving Stem Cell Transplants from Mismatched Unrelated Donors


Full Title

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (NMDP IRB)


Graft-versus-host disease (GVHD) is a problem that can happen after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body and cause serious health problems.

Cyclophosphamide is a chemotherapy drug often used to lower the chance of GVHD after a stem cell transplant. However, it has side effects. In this study, researchers are assessing a lower dose of cyclophosphamide. They hope it has fewer side effects but works just as well to prevent GVHD.

The people in this study are getting a stem cell transplant as treatment for a blood cancer. The transplant is coming from an unrelated donor who is not a perfect match.

Who Can Join

To join this study, there are a few conditions. You must:

  • Be scheduled for a stem cell transplant from a mismatched unrelated donor as treatment for a blood cancer.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Brian Shaffer’s office at 646-608-3737.




Phase II (phase 2)



ClinicalTrials.gov ID